Wave Life Sciences WVE 深 沪
已收盘 09-25 16:00:00 美东时间
3.78
-0.180
-4.55%
华盛通- 最 高4.00
- 今 开4.00
- 成交量 406.68万股
- 最 低 3.745
- 昨 收 3.96
- 总市值 7.45亿
- 52周最高 21.73
- 市盈率 静 --
- 换手率 2.06%
- 52周最低 3.745
- 委 比 90.34%
- 总股本 1.97亿
- 历史最高 56.00
- 量 比 1.23
- 振 幅 6.44%
- 历史最低 1.16
- 每 手 1
- 风险率 3.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Raymond James analyst C. Gregory Peters downgraded Accelerant Holdings (NYSE:ARX) from Market Per...
09-23 21:09
JP Morgan Downgrades Wave Life Sciences to Neutral
JP Morgan analyst Tessa Romero downgrades Wave Life Sciences (NASDAQ:WVE) from Overweight to Neutral.
09-23 20:19
Wave Life Sciences Starts Phase 2a Clinical Study Of WVE-007 To Treat Obesity
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tir...
09-23 19:30
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Wave Life Sciences appoints Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk brings extensive experience from Sanofi, Blackstone, and Pfizer in business development and strategic partnerships. She will lead business development, corporate development, and alliance management at Wave, supporting the company's growth and RNA medicines platform. Dr. Vnuk received a stock option to purchase 375,000 shares as part of her compensation.
09-22 11:30
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
<p>Wave Life Sciences, Inc. has completed its redomiciliation process, transitioning its parent company from Singapore to a Delaware corporation. The process was finalized on August 7, 2026, with all ordinary shares of Wave Life Sciences Ltd. exchanged one-for-one for common stock of the Delaware corporation. The company's shares will continue trading under the symbol "WVE" on NASDAQ starting August 10, 2026. The redomiciliation is not expected t...
08-10 12:30
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has appointed David Butler, PhD, to its Strategic Advisory Board (SAB), bringing over 20 years of experience in oligonucleotide therapeutics, including siRNA and mRNA-based technologies. Butler, previously CTO at Hongene Biotech and with roles at Wave Life Sciences and Alnylam, will support Codexis' growth in enzymatic manufacturing. Carole Cobb is stepping down from the SAB after significant contributions. Codexis leverages its Cod...
08-03 13:00
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $15 to $12.
07-31 21:02
Wave Life Sciences posts Q2 results, pipeline update
The latest announcement is out from Wave Life Sciences ( ($WVE) ). Wave Life Sc...
07-30 19:57
